PITTSBURGH, Dec. 18, 2020 /PRNewswire/ -- Viatris
Inc. (NASDAQ: VTRS) today announced that the U.S. District
Court for the District of Kansas
entered summary judgment in Mylan's favor in the lawsuit brought
against it by Sanofi related to its EpiPen® products.
Viatris is extremely pleased with this significant action by the
Court as it rejects Sanofi's baseless attempts to argue that Mylan
used anticompetitive practices to market EpiPen and goes a long way
in supporting the Company's commitment to vigorously defend itself
against unfounded claims.
For the past three years, Sanofi, one of the world's largest
pharmaceutical companies, has unjustly pursued money damages and
attempted to blame Mylan for Sanofi's own failures in marketing
Auvi-Q. The Court's favorable judgment should put an end to this
attempt by Sanofi to advance a false narrative against Mylan and to
use the antitrust laws to punish, rather than promote, competition.
More than five years ago, Sanofi completely recalled Auvi-Q from
the market and decided to return the product to the inventor after
the product was found to potentially have inaccurate dosage
delivery.
About EpiPen
EpiPen is used to treat life-threatening
allergic reactions. Mylan has worked to allow access to Epinephrine
in schools and public entities, so it can be readily available for
any child who needs it. Mylan has given away more than 1 million
EpiPen products to schools across America. These free pens have
been used thousands of times, potentially saving lives.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare
company, empowering people worldwide to live healthier at every
stage of life. We provide access to medicines, advance
sustainable operations, develop
innovative solutions and leverage our
collective expertise to connect more people to more
products and services through our one-of-a-kind Global
Healthcare GatewayTM. Formed in November 2020 through the combination of Mylan
and Pfizer's Upjohn business, Viatris brings together
scientific, manufacturing and distribution expertise with
proven regulatory, medical and commercial capabilities to
deliver high-quality medicines to patients in more than 165
countries and territories. Viatris' portfolio comprises more
than 1,400 approved molecules across a wide range of therapeutic
areas, spanning both non-communicable and infectious diseases,
including globally recognized brands, complex generic and branded
medicines, a growing portfolio of biosimilars and a variety of
over-the-counter consumer products. With a global workforce
of approximately 45,000, Viatris is headquartered in
the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
Twitter
at @ViatrisInc, LinkedIn and YouTube.
View original
content:http://www.prnewswire.com/news-releases/mylan-wins-summary-judgment-in-epipen-litigation-brought-by-sanofi-301196143.html
SOURCE Viatris Inc.